2Q 2025 Earnings July 30, 2025 forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward- looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes, unless required by law. The guidance in this presentation is only effective as of the date given and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Distribution or r ...

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano (877) 281-6642 (toll free) (908) 541-3785 ir@bauschhealth.com corporate.communications@bauschhealth.com BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2025 RESULTS BAUSCH HEALTH EXCLUDING BAUSCH + LOMB SECOND QUARTER 2025 RESULTS LAVAL, QC, July 30, 2025 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2025 financial results and other key updates from ...

Core Viewpoint - Bausch Health Companies Inc. has agreed to acquire DURECT Corp, focusing on the development of larsucosterol, a novel therapeutic molecule for alcoholic hepatitis, which currently lacks FDA or EMA approved treatments [1][2][3]. Group 1: Acquisition Details - Bausch Health will pay $1.75 per share in an all-cash transaction, totaling approximately $63 million, with potential milestone payments of up to $350 million [3]. - The acquisition is expected to close in the third quarter of 2025 [6]. Group 2: Clinical Development - A registrational Phase 3 program is planned to evaluate the safety and efficacy of larsucosterol for severe alcoholic hepatitis, with a primary endpoint of 90-day survival [3][4]. - The trial will be randomized, double-blind, placebo-controlled, and will incorporate feedback from the FDA [4]. Group 3: Complementary Programs - The acquisition complements Bausch Health's ongoing RED-C clinical program, which assesses rifaximin SSD for delaying the onset of hepatic encephalopathy hospitalization and all-cause mortality [5]. - Patient enrollment in two global Phase 3 studies for the RED-C program is complete, with results expected in early 2026 [5]. Group 4: Financial Context - Bausch Health is addressing its $21 billion debt, with a third due by 2027, and previously considered selling Bausch + Lomb Corp as part of this strategy [6]. - At the time of publication, Bausch Health's stock was down 0.36% at $6.87, while DURECT's stock rose 238.34% to $1.87 [6].

Core Insights - Bausch Health (BHC) is identified as a unique case study in the pharmaceutical industry, with a global presence and registration in Canada [1] Company Overview - Bausch Health is recognized as a significant player in the global pharmaceutical market, indicating its broad operational scope and influence [1] Analyst Background - The analysis is conducted by an experienced investment professional with over six years in equity analysis across various sectors, emphasizing a strong foundation in financial reporting and market value identification [1]

Core Viewpoint - Bausch Health Companies Inc. (BHC) reported disappointing first-quarter 2025 results, with earnings and revenues missing expectations, leading to a 3.81% decline in share price [1][15]. Financial Performance - Adjusted earnings per share were 59 cents, below the Zacks Consensus Estimate of 83 cents and down from 60 cents in the same quarter last year [1]. - Total revenues reached $2.26 billion, a 5% year-over-year increase, but missed the Zacks Consensus Estimate by 0.54% [1]. - Excluding foreign exchange impacts, acquisitions, and divestitures, organic revenue growth was 6% [2]. Segment Performance - Salix segment revenues were $542 million, up 9% year over year, but missed estimates [4][5]. - International revenues totaled $262 million, down 1% year over year, missing estimates but showing 5% organic growth [6]. - Solta Medical reported revenues of $113 million, a 28% increase year over year, beating estimates [7]. - Bausch + Lomb revenues were $1.14 billion, up 3% year over year, but missed estimates [10]. Pipeline Development - The phase II study on amiselimod for ulcerative colitis has completed enrollment, with a phase III study protocol submitted to the FDA [11]. - Phase III studies on rifaximin for hepatic encephalopathy are ongoing, with top-line results expected by early 2026 [12]. - The Clear and Brilliant Touch program for skin rejuvenation is advancing with multiple international approvals [13]. Guidance Update - BHC expects 2025 revenues to be between $9.950 billion and $10.200 billion, slightly up from previous guidance [14]. Debt Situation - As of March 31, 2025, BHC's debt obligations were $21.5 billion, with a cash balance of $1.1 billion [15].

Core Insights - Bausch Health reported $2.26 billion in revenue for Q1 2025, a year-over-year increase of 4.9%, with EPS remaining unchanged at $0.59 compared to the previous year [1] - The revenue fell short of the Zacks Consensus Estimate of $2.27 billion, resulting in a surprise of -0.54%, while the EPS missed the consensus estimate of $0.83 by -28.92% [1] Revenue Breakdown - Bausch + Lomb - Ophthalmic Pharmaceuticals: $267 million, below the estimate of $285.29 million, with no year-over-year change [4] - Solta Medical: $113 million, exceeding the estimate of $105.12 million, representing a year-over-year increase of 28.4% [4] - Bausch + Lomb - Vision Care: $656 million, slightly below the estimate of $657.80 million, with a year-over-year increase of 3.3% [4] - Total Bausch Health (excluding B+L): $1.12 billion, matching the estimate, with a year-over-year increase of 6.5% [4] - Total Bausch + Lomb revenues: $1.14 billion, below the estimate of $1.16 billion, with a year-over-year increase of 3.5% [4] - Diversified Products: $205 million, exceeding the estimate of $201.28 million, with a year-over-year increase of 1.5% [4] - Bausch + Lomb - Surgical: $214 million, slightly above the estimate of $212.34 million, with a year-over-year increase of 8.6% [4] - Salix: $542 million, below the estimate of $544.67 million, with a year-over-year increase of 8.6% [4] - International revenues: $262 million, below the estimate of $267.63 million, with a year-over-year decrease of 1.1% [4] - Product sales: $2.23 billion, slightly below the estimate of $2.24 billion, with a year-over-year increase of 4.6% [4] - Other revenues: $32 million, exceeding the estimate of $22.60 million, with a year-over-year increase of 33.3% [4] - Diversified Products - Dentistry: $23 million, below the estimate of $23.77 million, with a year-over-year decrease of 4.2% [4] Stock Performance - Bausch shares have returned -11.8% over the past month, compared to the Zacks S&P 500 composite's -0.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Viewpoint - Bausch Health (BHC) reported quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.83 per share, indicating an earnings surprise of -28.92% [1] Financial Performance - The company posted revenues of $2.26 billion for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 0.54%, compared to revenues of $2.15 billion a year ago [2] - Over the last four quarters, Bausch has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Bausch shares have declined approximately 31.6% since the beginning of the year, contrasting with the S&P 500's decline of -5.5% [3] - The current Zacks Rank for Bausch is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.05 on revenues of $2.46 billion, and for the current fiscal year, it is $4.26 on revenues of $9.92 billion [7] - The estimate revisions trend for Bausch is mixed, and changes in estimates for the coming quarters and current fiscal year are anticipated following the recent earnings report [6][7] Industry Context - The Medical - Generic Drugs industry, to which Bausch belongs, is currently in the top 20% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 98-0448205 (State or o ...

Exhibit 99.1 Investor Contact: Media Contact: Garen Sarafian Katie Savastano (877) 281-6642 (toll free) (908) 541-3785 ir@bauschhealth.com corporate.communications@bauschhealth.com BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2025 RESULTS BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST QUARTER 2025 RESULTS LAVAL, QC, April 30, 2025 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2025 financial results and other key updates from th ...

Company Overview - Bausch Health (BHC) is expected to report a year-over-year increase in earnings, with a projected EPS of $1.44, reflecting a change of +144.1% [3] - Revenues are anticipated to reach $2.27 billion, marking a 5.5% increase from the previous year [3] Earnings Expectations - The consensus EPS estimate has been revised down by 3.44% over the last 30 days, indicating a bearish sentiment among analysts [4] - The Most Accurate Estimate for Bausch is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -35.93%, which complicates the prediction of an earnings beat [10][11] Historical Performance - In the last reported quarter, Bausch exceeded the consensus EPS estimate of $1.12 by delivering earnings of $1.15, resulting in a surprise of +2.68% [12] - Over the past four quarters, Bausch has beaten consensus EPS estimates two times [13] Market Sentiment - The stock's movement is contingent on the upcoming earnings report, with potential for an increase if results exceed expectations, while a miss could lead to a decline [2] - Despite the negative Earnings ESP, the stock currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [11] Industry Context - BridgeBio Pharma (BBIO), a peer in the Zacks Medical - Generic Drugs industry, is expected to report a significant decline in earnings, with an EPS estimate of $0.91, reflecting a year-over-year change of -1,720% [17] - BridgeBio's revenues are projected to be $62.45 million, down 70.4% from the previous year [17] - The consensus EPS estimate for BridgeBio has been revised down by 1.8% over the last 30 days, but a higher Most Accurate Estimate has resulted in a positive Earnings ESP of 0.24% [18]